AI & DIGITAL ONCOLOGY
AI-driven multimodal strategy improves risk stratification in early breast cancer
Integrating digital pathology with genomic and clinical data may enhance prediction of late recurrence and refine selection for adjuvant treatment intensification in HR-positive, HER2-negative disease
Customised app shows promise for monitoring prostate cancer patients in real-time
A pilot study reports high levels of acceptance and compliance despite an older patient population
Why AI-powered trial matching alone will not fix oncology trial recruitment
AI-powered trial matching helps identify relevant trials faster, but recruitment often fails beyond the algorithm. Limited cross-site trial discovery, outdated recruitment information and fragmented referral pathways continue to prevent potentially eligible patients from participating in relevant trials.
LATEST NEWS
Sustained quality-of-life benefits reported with first-line antibody-drug conjugate in triple negative breast cancer
Patient-reported outcomes show that datopotamab deruxtecan also improved patient functioning and symptom control compared to chemotherapy
Piccart: “Academic research is losing ground very rapidly”
At a senior stage of her career in oncology, Prof. Martine Piccart remains deeply committed in supporting young oncologists in cancer research
How to sequence antibody–drug conjugates in metastatic breast cancer? Target switching alone may not be the answer
The first prospective phase II trials evaluating TOPO1 ADC after prior TOPO1 ADC therapy confirm the emergence of cross-resistance
OPINIONS
Optimal sequencing of immunotherapy in MSI-H/dMMR colon cancer remains uncertain
Dominik Modest
Can digital tools improve personalised support for adolescents and young adults with cancer?
Ivana Bozovic-Spasojevic
The management of invasive lobular breast cancer is evolving
Rinath Jeselsohn
Phenotypic profiling in pancreatic cancer: promise meets practical limits
Alejandro González Sánchez
Novel emerging targets, new treatment opportunities
Jonathan Lim
OPINIONS
Optimal sequencing of immunotherapy in MSI-H/dMMR colon cancer remains uncertain
Dominik Modest
Can digital tools improve personalised support for adolescents and young adults with cancer?
Ivana Bozovic-Spasojevic
The management of invasive lobular breast cancer is evolving
Rinath Jeselsohn
Phenotypic profiling in pancreatic cancer: promise meets practical limits
Alejandro González Sánchez
Novel emerging targets, new treatment opportunities
Jonathan Lim